The recent US court ruling regarding a patent dispute between Zydus Lifesciences and Lupin has drawn significant attention from both the pharmaceutical industry and investors involved in share market investment.
Both companies, major players in the Indian pharmaceutical sector, were affected by the court's decision, which revolved around the launch of their generic versions of the drug Mirabegron in the US market. This legal development has led to shifts in their stock prices, making it a crucial event for those monitoring share market investment trends.
Background: The US court patent ruling
Zydus Lifesciences and Lupin are the only two companies that have launched generic versions of Mirabegron in the US after receiving approval from the US FDA. Mirabegron is used to treat overactive bladder (OAB) and is a significant drug in the US pharmaceutical market. The original maker of Mirabegron, Astellas Pharma Inc., sued both Zydus and Lupin to block their generic versions, claiming patent infringement. A US district court initially ruled in favour of Zydus and Lupin, invalidating the '780 patent held by Astellas. However, the US Court of Appeals for the Federal Circuit later stated that the district court had erred in its decision-making process.
This ruling has put Zydus and Lupin in a complex situation regarding their future sales of generic Mirabegron. As the two companies move forward, investors in share market investment are closely monitoring the impact of this legal battle on their stock performance.
Zydus Life: Share market performance
Zydus Lifesciences has seen significant movement in its share prices following the US court's ruling. The company was one of the first to launch the generic version of Mirabegron in 25 mg dosages and is preparing to launch the 50 mg version imminently. According to InCred Equities, Zydus is expected to generate revenues of $135 million in FY25 and $35 million in FY26 from Mirabegron sales. However, the ongoing litigation has raised uncertainty about these projections, which could influence share market investment strategies.
In light of the ruling, InCred Equities maintained its 'add' rating on Zydus but reduced its target price to ₹1,330 per share. Despite the legal uncertainties, the brokerage does not foresee any immediate risks to the company's earnings estimates. However, there is a possibility that Zydus may face damages if it loses the legal battle with Astellas, which could further affect the company's stock performance and investor sentiment regarding share market investment in the pharmaceutical sector.
Lupin: Share market performance
Like Zydus, Lupin has also faced stock price volatility following the US court's ruling on the Mirabegron patent dispute. Lupin was quick to launch its generic version of Mirabegron at risk, and the company's earnings are expected to benefit significantly from the product if allowed to continue selling it. For investors focused on share market investment, Lupin's involvement in this case is important as the outcome of the legal proceedings could directly impact the company's future revenue.
InCred Equities has maintained its 'add' rating on Lupin, with a target price of ₹2,329 per share. The brokerage anticipates that Lupin will generate revenues of $70 million in FY25 and $10 million in FY26 from the sale of Mirabegron. However, should the court ultimately rule against Lupin, the company may be required to pay damages, potentially reducing its profits and negatively impacting its stock price. This presents a level of risk for investors considering share market investment in Lupin.
Brokerage assessments of the court ruling
Various brokerages have provided their insights into the potential consequences of the US court's patent ruling for both Zydus Lifesciences and Lupin. These assessments are vital for investors involved in share market investment, as they offer guidance on how the companies' stocks may perform in the future, depending on the outcome of the litigation.
InCred Equities noted that while the court's decision creates uncertainty, it does not foresee an immediate risk to the earnings estimates of either company. Meanwhile, JPMorgan suggested that although the ruling adds complexity to the legal proceedings, it is unlikely to impact the product strategies of Zydus and Lupin in the near term. Both brokerages indicated that the court case might delay the entry of additional generic competitors for six to nine months, allowing Zydus and Lupin to continue generating revenue from their Mirabegron sales.
Key takeaways
the US court's ruling on the patent dispute between Zydus Lifesciences and Lupin has introduced a significant level of uncertainty in the pharmaceutical sector, with both companies now navigating the complexities of ongoing litigation. For those involved in share market investment, this legal development serves as a critical point of interest, with potential ramifications on stock performance and long-term revenue projections.
While brokerages maintain cautious optimism, acknowledging the potential for continued sales in the near term, the possibility of future damages and legal outcomes remains a pivotal factor for investors monitoring share market investment trends surrounding these pharmaceutical giants.
For android only